Business Wire

WA-TANIUM

6.1.2022 21:41:12 CET | Business Wire | Press release

Share
Tanium: The Leading Corporate Solution to Fully Identify and Remediate Log4j Vulnerabilities

Industry experts are naming Log4j one of the most severe internet and computer vulnerabilities they have encountered. The United States Cyber Security and Infrastructure Security Agency (CISA) Director stated that the Log4j vulnerability: “…is one of the most serious I’ve seen in my entire career, if not the most serious.”

Log4j is the perfect storm of severity, pervasiveness, and ease of exploitability. It is an open-source code library widely used inside commercial and open-source software applications. The recently discovered vulnerability allows hackers to take complete control of affected endpoints with a single line of code. As a result, finding and fixing every single instance of Log4j and applications that rely on it is critical for corporate networks.

The key to finding all instances of Log4j is the ability to look inside every file in a corporate network and Tanium is the only solution that, in minutes, can look inside every file, and find every instance of Log4j, at scale today.

Tanium is supporting organizations globally in the eradication of Log4j vulnerabilities. The Tanium Platform uniquely enables organizations to manage their exposure by:

  • Looking inside nested archive folders and files for vulnerabilities
  • Finding references to Log4j even if they were renamed (maliciously or by design)
  • Automating software upgrades and patches at scale to all vulnerable systems
  • Watching, alerting, and remediating any new instance of the vulnerability that is inadvertently introduced post-cleanup

Ring Power Corp. was able to scan every file and folder and find every single instance of Log4j with their entire environment in only minutes. “Tanium Reveal has been critical to us in responding to Log4j. Nobody else was able to search for references to the impacted library in common file formats and detect instances of exploitation. With Tanium, we accomplished in 30 minutes what would have taken months.” - Kevin Bush, VP of IT at Ring Power Corp.

Salisbury University stated “We saw first-hand the strength of Tanium during the Log4j vulnerability crisis. Tanium made us aware of many endpoints that were vulnerable to Log4j through user-installed tools and applications that we weren’t aware of.” – Steven Blankenship, Director of IT

To set up a Tanium evaluation of your environment for the Log4j vulnerability, please contact us at https://www.tanium.com/log4j/ .

About Tanium

Tanium is the platform that the most demanding and complex organizations trust to gain visibility and control across all endpoints in on-premises, cloud and hybrid environments. Tanium addresses today’s increasing IT challenges with high fidelity endpoint data — giving IT operations, security and risk teams confidence to quickly manage, secure and protect their networks at scale. Nearly half of the Fortune 100, top retailers and financial institutions, and multiple branches of the U.S. Armed Forces trust Tanium to help see and control every endpoint, everywhere. That’s the power of certainty. Tanium has been named to the Forbes Cloud 100 list of “Top 100 Private Companies in Cloud Computing” for six consecutive years and ranks on FORTUNE’s list of the “Best Large Workplaces in Technology 2021.” Visit www.tanium.com and follow us on LinkedIn and Twitter .

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release

Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result

Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release

Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said

SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release

In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin

Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release

Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th

SES Publishes FY2025 EU Taxonomy Restatement31.7.2026 07:30:00 CEST | Press release

SES today published a restatement of its FY2025 EU Taxonomy (Article 8) disclosure. The restatement updates the FY2025 EU Taxonomy disclosure included in the 2025 Annual Report and supersedes the previously published disclosure. The FY2025 EU Taxonomy Restatement is available on the SES website: https://www.ses.com/sites/ses_v2/files/investor-files/2026-07/EU_Taxonomy_Report_Restatement_2025.pdf Follow us on: X | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where they are. With integrated multi-orbit satellites and our global terrestrial network, we deliver resilient, seamless connectivity and the highest quality video content to those shaping what’s next. Following our Intelsat acquisition, we now offer more than 100 years of combined global industry l

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye